BloembergenW.E., PortF.K., MaugerE.A., WolfeR.A.A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis.J Am Soc Nephrol1995; 6: 184–91.
2.
WieslanderA.P., DepppischR., SvenssonE., ForsbackG., SpeidelR., RippeB.In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis.Perit Dial Int1995; 15: 158–64.
3.
LamperiS., CarozziS.Defective opsonic activity of peritoneal effluent during CAPD: importance and prevention.Perit Dial Bull1986; 6: 87–92.
4.
CollinsM.S., HectorR.F., RobyR.E., EdwardsA.A., LadehoffD.K., DorseyJ.H.Prevention of gram-negative and grampositive infections with 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection with intravenous pseudomonas immunoglobulin G and ciprofloxacinin an animal model.Infection1987; 15: S51–9.
5.
CarozziS., NasiniM.G., KunklA., CantarellaS., LamperiS.Response of CAPD patients with a high incidence of peritonitis to intraperitoneal immunoglobulin therapy.ASAIO Trans1988; 34: 635–9.
6.
JesdinskyH.J., TempelG., CastrupH.J., SeifertJ.Cooperative group of additional immunoglobulin therapy in severe bacterial infections.Klin Wochenschr1987; 65: 1132–8.
7.
Nakayamal, KawaguchiH., YamajiE., AkiedaY., ItokawaK.Therapeutic effect of a new human immunoglobulin SM-4300 on the severe infections in surgical patients.Jpn J Antibiot1985; 38: 2617–21.
